

Pemetrexed

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ADJUSTMENTS

Quality of life

No QoL benefit

Serious and disabling adverse effects

Other adjustments

Pemetrexed

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

Experimental Arm: Pemetrexed

Control Arm: Placebo



